Shares of TearLab Corporation (NASDAQ:TEAR) have earned an average rating of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $5.75.

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of TearLab Corporation in a report on Tuesday, May 16th. Rodman & Renshaw reduced their target price on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, May 16th. Finally, Zacks Investment Research lowered shares of TearLab Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th.

WARNING: “TearLab Corporation (NASDAQ:TEAR) Given Consensus Rating of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/17/tearlab-corporation-nasdaqtear-given-consensus-rating-of-buy-by-analysts.html.

Shares of TearLab Corporation (TEAR) remained flat at $1.70 during trading on Monday. The company’s stock had a trading volume of 121,720 shares. The firm has a 50 day moving average of $1.90 and a 200 day moving average of $3.62. The stock’s market capitalization is $9.75 million. TearLab Corporation has a one year low of $1.55 and a one year high of $9.00.

TearLab Corporation (NASDAQ:TEAR) last released its earnings results on Monday, May 15th. The medical research company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $7.02 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The business’s revenue was down 1.5% compared to the same quarter last year. On average, equities research analysts forecast that TearLab Corporation will post ($2.82) EPS for the current year.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Analyst Recommendations for TearLab Corporation (NASDAQ:TEAR)

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.